Nurix Therapeutics, Inc.

Contributing Author

Recent Articles by Nurix Therapeutics, Inc.

Sep-01	Nurix Therapeutics to Participate in Upcoming September Investor Conferences NRIX GlobeNewswire
Aug-20	Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer NRIX GlobeNewswire
Aug-04	Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader NRIX +6.33% GlobeNewswire
Aug-04	Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NRIX +6.33% GlobeNewswire
Jul-21	Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology NRIX GlobeNewswire
Jul-09	Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NRIX NRIX -6.60% GlobeNewswire
Jun-11	Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy NRIX +10.98% GlobeNewswire
Jun-08	Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology NRIX +6.83% GlobeNewswire
May-14	Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting NRIX GlobeNewswire
May-13	Nurix Therapeutics to Participate in Upcoming Investor Conferences NRIX GlobeNewswire
May-12	Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress NRIX GlobeNewswire
Apr-22	Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 NRIX GlobeNewswire
Apr-08	Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update NRIX GlobeNewswire
Apr-07	Nurix Therapeutics to Participate in Upcoming Investor Conference NRIX GlobeNewswire
Mar-23	Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting NRIX GlobeNewswire
Jan-28	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update NRIX -7.93% GlobeNewswire
Jan-12	Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases NRIX GlobeNewswire
Jan-05	Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference NRIX GlobeNewswire
Dec-08	Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrom Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition NRIX +18.68% GlobeNewswire
Dec-06	Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition NRIX GlobeNewswire
Dec-01	Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition NRIX GlobeNewswire
Nov-25	Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference NRIX GlobeNewswire
Nov-10	Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors NRIX GlobeNewswire
Nov-07	Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling NRIX GlobeNewswire
Nov-03	Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting NRIX GlobeNewswire
Oct-30	Nurix Therapeutics to Participate in Upcoming Investor Conferences NRIX +9.23% GlobeNewswire
Oct-27	Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock NRIX +8.03% GlobeNewswire
Oct-22	Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock NRIX GlobeNewswire
Oct-22	Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia NRIX GlobeNewswire
Oct-18	Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress NRIX GlobeNewswire
Oct-09	Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update NRIX +8.82% NRIX -10.13% GlobeNewswire
Sep-17	Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis NRIX GlobeNewswire
Aug-28	Nurix Therapeutics to Participate in Upcoming Investor Conferences NRIX GlobeNewswire
Jul-09	Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update NRIX +7.94% GlobeNewswire
Jul-07	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia NRIX GlobeNewswire
Jun-13	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NRIX GlobeNewswire
Jun-12	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM) NRIX -5.30% GlobeNewswire
Jun-06	Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) NRIX GlobeNewswire
Jun-02	Sanofi Exercises License Extension Option to Nurix's STAT6 Program NRIX +14.21% GlobeNewswire
May-28	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference NRIX GlobeNewswire
May-16	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NRIX GlobeNewswire
May-15	Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference NRIX GlobeNewswire
May-14	Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma NRIX GlobeNewswire

Nurix Therapeutics, Inc.

Recent Articles by Nurix Therapeutics, Inc.

Upgrade your Finviz experience